Opinion

Video

Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA

Author(s):

Stephen J. Freedland, MD,Eleni Efstathiou, MD, PhD

Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.

  1. Efstathiou: What are your impressions of the patient case? How would you evaluate and risk stratify this patient?
Related Videos
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

David Parkinson, MD, president, chief executive officer, ESSA
November 1st 2024

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Bradley C. Carthon, MD, PhD
October 30th 2024

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer
October 30th 2024

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer